Last reviewed · How we verify
NCT04044391
Use of Magnetocardiography in Evaluation of Patients Going for Cardiac Catheterization
trial testing CardioFlux Magnetocardiograph in Acute Coronary Syndrome in 101 participants. Terminated before completion.
1 March 2020
Quick facts
| Lead sponsor | Genetesis Inc. |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 101 |
| Start date | 15 May 2019 |
| Primary completion | 1 March 2020 |
| Estimated completion | 4 May 2020 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- CardioFlux Magnetocardiograph
Conditions studied
- Acute Coronary Syndrome — all drugs for Acute Coronary Syndrome →
- Coronary Artery Stenosis — all drugs for Coronary Artery Stenosis →
- Myocardial Ischemia — all drugs for Myocardial Ischemia →
Sponsor
Genetesis Inc.
Who can join
18 and older, any sex, with Acute Coronary Syndrome or Coronary Artery Stenosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicenter, prospective trial to measure the test performance characteristics of the Magnetocardiography (MCG) CardioFlux cardiac diagnostic system in detecting clinically significant coronary artery obstruction in patients with symptoms of suspected acute coronary syndrome or who present with a failed stress test with the intention of treat with cardiac catheterization.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04044391
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Coronary Syndrome
Currently open trials in the same condition.
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07230847 — A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug- · NA · recruiting
- NCT07032389 — A Polypill for Acute Coronary Syndrome · Phase 2 · recruiting
- NCT07102628 — Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronar · Phase 3 · recruiting
- NCT06416813 — Preventive Intervention Value of DCB in Vulnerable Coronary Atherosclerotic Plaques · NA · active not recruiting
Other Genetesis Inc. trials
Trials by the same sponsor.
- NCT06212466 — MCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2) · completed
- NCT06139094 — MCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR · completed
- NCT05868902 — A Registry of Cardiac PET and CardioFlux Magnetocardiography in Patients With Suspected Coronary Ischemia. · recruiting
- NCT05751915 — Magnetocardiography as a Noninvasive Diagnostic Strategy for Identifying Coronary Allograft Vasculopathy · unknown
- NCT05150054 — MCG as a Noninvasive Diagnostic Strategy for Suspected Coronary Microvascular Dysfunction · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04044391 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Genetesis Inc.
- Last refreshed: 26 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04044391.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing